OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
June 2, 2020
SAN FRANCISCO, CA – OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, today announced resumption of patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D).
OrphoMed paused screening of new patients on March 27, 2020, in response to the COVID-19 pandemic. Study screening will resume on a clinical investigational site-by-site basis as authorities lift shelter-in-place directives. Frank J. Steinberg, D.O., Head of Medical Oversight and founding Chief Medical Officer at OrphoMed, will work with PPD, a leading global contract research organization, and supporting organizations to ensure continued patient and staff safety.
“During the study screening hold, we worked diligently to continue the study as planned and to treat and evaluate patients already participating in the study safely and effectively,” said Dr. Steinberg. “We plan a staggered resumption of enrollment that is in line with federal and state guidelines and which will be on a site-by-site basis. We look forward to continued support from our investigators and study staff to efficiently complete the planned enrollment in this study.”
About OrphoMed, Inc.
OrphoMed is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by founder Nikhilesh Singh, Ph.D., OrphoMed is advancing ORP-101 and a pipeline of additional dimer conjugates. In May 2017, OrphoMed completed a $39 million Series A financing with New Enterprise Associates, Takeda Ventures, Pappas Capital and Relativity Healthcare. For more information please visit www.orphomed.com.
This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.